William Blair Investment Management LLC Sells 42,351 Shares of Glaukos Corporation $GKOS

William Blair Investment Management LLC cut its position in Glaukos Corporation (NYSE:GKOS) by 3.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,093,744 shares of the medical instruments supplier’s stock after selling 42,351 shares during the quarter. William Blair Investment Management LLC’s holdings in Glaukos were worth $89,195,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. UMB Bank n.a. boosted its holdings in Glaukos by 102.6% during the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 158 shares during the period. REAP Financial Group LLC bought a new position in shares of Glaukos in the third quarter worth about $40,000. AlphaQuest LLC lifted its position in shares of Glaukos by 5,754.5% during the 2nd quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock worth $67,000 after purchasing an additional 633 shares during the last quarter. SBI Securities Co. Ltd. boosted its stake in Glaukos by 42.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 1,205 shares of the medical instruments supplier’s stock valued at $98,000 after purchasing an additional 362 shares during the period. Finally, Smartleaf Asset Management LLC grew its stake in shares of Glaukos by 16.2% in the second quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after acquiring an additional 136 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Stock Performance

Shares of NYSE:GKOS opened at $120.01 on Monday. The business’s fifty day moving average price is $116.00 and its two-hundred day moving average price is $100.15. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $130.23. The stock has a market capitalization of $6.97 billion, a price-to-earnings ratio of -36.81 and a beta of 0.70. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.69 and a quick ratio of 4.06.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The company had revenue of $143.12 million for the quarter, compared to the consensus estimate of $132.16 million. During the same period in the previous year, the business posted ($0.40) earnings per share. The firm’s revenue was up 35.6% compared to the same quarter last year. As a group, analysts predict that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Insider Activity

In other Glaukos news, CEO Thomas William Burns sold 186,945 shares of the business’s stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $115.00, for a total value of $21,498,675.00. Following the transaction, the chief executive officer directly owned 153,775 shares in the company, valued at $17,684,125. The trade was a 54.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Aimee S. Weisner sold 15,000 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $117.38, for a total transaction of $1,760,700.00. Following the sale, the director directly owned 18,806 shares in the company, valued at $2,207,448.28. This represents a 44.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 325,000 shares of company stock worth $37,739,259 over the last ninety days. Corporate insiders own 6.40% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Wells Fargo & Company boosted their price objective on shares of Glaukos from $122.00 to $135.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. BTIG Research reissued a “buy” rating and set a $131.00 target price on shares of Glaukos in a research report on Wednesday, February 18th. Stephens boosted their price target on Glaukos from $115.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, January 2nd. Needham & Company LLC raised their price objective on Glaukos from $125.00 to $127.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Finally, Citigroup lifted their price objective on Glaukos from $113.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Glaukos currently has an average rating of “Moderate Buy” and a consensus price target of $133.69.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.